News : meda

View:
 

Found press releases

 

Collaboration with Omega Pharma for SB12

12/9/2011 2:00 AM EST  -   MEDA
Meda has signed a 5-year collaboration agreement with Omega Pharma for SB12 in France, Italy, Belgium and Greece. Omega Pharma is a Belgian company with a leading market position in the OTC segment in these countries.

SB12 is an oral care agent for bad breath. Meda has established SB12 as a market leader in the Nordic region. In 2012, Meda intends to launch SB12 in about ten markets across Europe under its own...

Meda acquires Treo

11/17/2011 7:39 AM EST  -   MEDA
Meda has agreed to acquire three well-established Nordic OTC drugs from McNeil AB/Cilag GmbH International, members of the Johnson & Johnson Consumer Companies. Treo is the main drug. Annual sales for all three products total approximately 210 MSEK.

Meda will acquire all rights to the drugs. The purchase price is 82 MEUR and the transaction is expected to be finalized within a couple of weeks.

"Meda’s position...

Meda AB (publ) – Interim report, January-September 2011

11/2/2011 3:00 AM EST  -   MEDA

· Group net sales reached SEK 9,400 million (8,561). At fixed currency rates, sales increased 19%.

· EBITDA rose to SEK 3,493 million (3,057[1]), corresponding to a 37.2% margin (35.7[1]). At fixed currency rates, EBITDA increased 24%[1].

· Operating profit amounted to SEK 1,986 million (1,772[1]).    

· Profit after tax totaled SEK 1,098 million (1,249). Excluding non-recurring effects, profit after tax...

Dymista filed in Europe

10/28/2011 7:20 AM EST  -   MEDA
The marketing authorization application for Dymista (a novel formulation of azelastine hydrochloride and fluticasone propionate) has been filed in Europe. The application uses a decentralized procedure and the reference member state is Germany.

Dymista is a nasal spray formulation for patients with symptomatic treatment of moderate to severe allergic rhinitis and rhinoconjuctivitis. The efficacy and safety of...

MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE

9/19/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply...

Meda AB (publ) – Interim report, January-June 2011

8/3/2011 2:00 AM EST  -   MEDA

· Group net sales reached SEK 6,177 million (5,986). At fixed currency rates, sales increased 14%.

· EBITDA rose to SEK 2,319 million (2,191[1]), corresponding to a 37.5% margin (36.6). At fixed currency rates, EBITDA increased 17%.

· Operating profit amounted to SEK 1,345 million (1,348 [1]).

· Profit after tax totaled SEK 753 million (1,039). Excluding non-recurring effects, profit after tax totaled SEK...

Meda acquires remaining Xerese rights in North America

6/29/2011 2:30 AM EST  -   MEDA
In February 2010, Meda in-licensed exclusive North American rights to Xerese – a patented product for treatment of cold sores (herpes labialis). Under that agreement, Meda pays the collaboration partner Medivir AB mid-teens and minimum royalties on net sales. Today, Meda has acquired all rights for Xerese in North America and the royalties have been reduced to zero. The purchase price was 45 MUSD. Under the terms of...

Acquisition of Elidel completed

5/12/2011 2:15 AM EST  -   MEDA
Meda’s acquisition of global rights for Elidel (pimecrolimus 1% cream) – announced on 7 April 2011 - has been completed.

About Elidel

Elidel is a patent protected, specialty focused product for the treatment of atopic dermatitis (AD). Depending on the country, Elidel is indicated as a second-line therapy for the short and long-term management of the signs and symptoms of mild to moderate AD in adults and children...

Meda files complaint against 3M and claims damages

12/23/2010 2:00 AM EST  -   MEDA
Meda has filed a complaint against 3M and claims damages for breach of agreement in connection with Meda’s acquisition of 3M’s European pharmaceutical division in 2007. Meda’s claims are based upon 3M’s failure to disclose an essential agreement that it had entered into with the French authorities regarding the sale of Tambocor in France. This undisclosed agreement forced Meda, after the acquisition, to concede to...

Medivir’s U.S. commercialisation partner Meda presents positive Xerese™ data at ...

12/8/2010 1:00 AM EST  -   Medivir
Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that its U.S. commercialisation partner, Meda, has presented virolology data from the phase 3 programme on Xerese™/Xerclear®, Medivir’s unique cold sore treatment, at the 45th American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition, Anaheim, USA, 5-9...